{"slug":"regulation","tag":"regulation","variants":["regulation"],"description":"No description yet","count":15,"kinds":{"person":14,"technology":1},"related":[{"slug":"leadership","tag":"leadership","shared":13},{"slug":"health-technology-assessment","tag":"health technology assessment","shared":4},{"slug":"government","tag":"government","shared":3},{"slug":"clinician-scientist","tag":"clinician-scientist","shared":2},{"slug":"australia","tag":"australia","shared":1},{"slug":"cell-therapy","tag":"cell-therapy","shared":1},{"slug":"data-sharing","tag":"data sharing","shared":1},{"slug":"data-standards","tag":"data standards","shared":1},{"slug":"drug-approval","tag":"drug approval","shared":1},{"slug":"drug-development","tag":"drug development","shared":1},{"slug":"paediatric-oncology","tag":"paediatric oncology","shared":1},{"slug":"rejuvenation","tag":"rejuvenation","shared":1}],"records":[{"id":"emer-cooke","kind":"person","name":"Emer Cooke","route":"/people/emer-cooke/","tldr":"Executive Director of the European Medicines Agency since November 2020, overseeing EU approval of cancer medicines."},{"id":"lawrence-tallon","kind":"person","name":"Lawrence Tallon","route":"/people/lawrence-tallon/","tldr":"Chief Executive of the UK Medicines and Healthcare products Regulatory Agency, the body that approves and monitors cancer medicines and devices in the UK."},{"id":"sonja-optendrenk","kind":"person","name":"Sonja Optendrenk","route":"/people/sonja-optendrenk/","tldr":"Impartial chair of Germany's Federal Joint Committee (G-BA), the body that decides which treatments statutory health insurance covers."},{"id":"thomas-kaiser","kind":"person","name":"Thomas Kaiser","route":"/people/thomas-kaiser/","tldr":"Physician who directs IQWiG, the German institute that produces the benefit assessments underpinning cancer drug pricing and coverage decisions."},{"id":"chris-decker","kind":"person","name":"Chris Decker","route":"/people/chris-decker/","tldr":"Leads CDISC, the non-profit that sets the clinical trial data standards required by FDA and PMDA, including oncology-specific therapeutic area guides."},{"id":"gilles-vassal","kind":"person","name":"Gilles Vassal","route":"/people/gilles-vassal/","tldr":"Gustave Roussy paediatric oncologist and past SIOPE president who leads its oncopolicy work and helped shape European paediatric medicines regulation."},{"id":"joseph-ross","kind":"person","name":"Joseph S. Ross","route":"/people/joseph-ross/","tldr":"Yale health policy researcher on the YODA Project leadership team, known for work on FDA regulation and trial transparency."},{"id":"yasuhiro-fujiwara","kind":"person","name":"Yasuhiro Fujiwara","route":"/people/yasuhiro-fujiwara/","tldr":"Medical oncologist who heads Japan's Pharmaceuticals and Medical Devices Agency, the national drug and device regulator."},{"id":"lionel-collet","kind":"person","name":"Lionel Collet","route":"/people/lionel-collet/","tldr":"Physician and former university president who chairs the Haute Autorité de Santé, France's health technology assessment and quality body."},{"id":"jean-lessi","kind":"person","name":"Jean Lessi","route":"/people/jean-lessi/","tldr":"Director General of the Haute Autorité de Santé, responsible for the agency's operations since January 2024."},{"id":"shalene-curtis-micallef","kind":"person","name":"Shalene Curtis-Micallef","route":"/people/shalene-curtis-micallef/","tldr":"Senior public servant who has led Health Canada as Deputy Minister since January 2026, after serving as Canada's Deputy Minister of Justice."},{"id":"anthony-lawler","kind":"person","name":"Anthony Lawler","route":"/people/anthony-lawler/","tldr":"Head of Australia's medicines and medical devices regulator, the body that approves cancer drugs for the Australian market."},{"id":"rajeev-singh-raghuvanshi","kind":"person","name":"Rajeev Singh Raghuvanshi","route":"/people/rajeev-singh-raghuvanshi/","tldr":"India's Drugs Controller General, who heads the Central Drugs Standard Control Organisation, the national regulator for medicines, medical devices and clinical trials."},{"id":"huang-guo","kind":"person","name":"Huang Guo","route":"/people/huang-guo/","tldr":"Commissioner of China's National Medical Products Administration, the regulator whose Center for Drug Evaluation reviews new cancer drugs for the Chinese market."},{"id":"rejuv-tx-gene-modified-follow-up","kind":"technology","name":"Long-term follow-up for gene-modified cell products: fifteen years, and why","route":"/technologies/rejuv-tx-gene-modified-follow-up/","status":"standard-of-care","tldr":"If you were given a treatment in which your own cells were genetically modified, you are expected to be followed up for fifteen years. Not because something is known to go wrong, but because the gene is inserted permanently and the only honest way to find out what happens over a lifetime is to look."}]}